JPRN-UMIN000002897已完成2 期
Phase II Trial of Bevacizumab in Combination with XELOX in Colorectal Cancer Patients with Liver Metastases (H2, H3) - NCCSG-05
iigata Colorectal cancer Chemotherapy Study Group (NCCSG)0 个研究点目标入组 20 人开始时间: 2009年12月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.clinical or radiological evidence of CNS metastases. 2.current or previous (within the last 1 year) history of cerebrovascular disease 3.major surgical procedure, open biopsy or significant traumatic injury except for CV-port procedure within 28 days prior to Day 0 4.serious non-healing fracture 5.current or previous (within the last 1 year) history of GI perforation 6.serious non-healing ulcer 7.evidence of bleeding diathesis or coagulopathy. 8.current or recent (within 10 days prior to enrllment) ongoing treatment with anticoagulants for therapeutic purposes 9.ongoing treatment with aspirin (> 325 mg/day) 10.clinically significant (i.e. active) cardiovascular disease, or past or current history (within the last 1 year) of myocardial infarction 11.uncontrolled hypertension 12. serious renal failure, 1+ or higher proteinuria within 2 weeks prior to enrollment 13.uncontrolled pleural and/or peritoneal effusion 14.past or current history (within the last 5 years) of malignancies except for the indication under this study and curatively treated: - Basal and squamous cell carcinoma of the skin - In-situ carcinoma of the cervix 15. neuropathy >= Grade 1 according to the Common Toxicity Criteria of the National Cancer Institute, version 3. 16.interstitial lung disease, or pulmonary fibrosis 17. diarrhea >= Grade 2 according to the Common Toxicity Criteria of the National Cancer Institute, version 3. 18.uncontrolled infection 19.history of organ transplantation 20.pregnancy (positive serum pregnancy test) and lactation 21.serious drug hypersensitivity or a history of drug allergy 22.history of adverse events related to fluorouracil 23.Any other serious or uncontrolled illness which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial
研究者
相似试验
招募中
1 期
Phase I/II Trial of Bevacizumab in Combination With FOLFOXIRI As First-Line Therapy in Colorectal Cancer Patients With Liver Metastasescolorectal cancer patients with fore or more liver metastasesJPRN-UMIN000005413Yokohama City University School of Medicine23
已完成
不适用
Phase II Study of Bevacizumab in Combination with First-line Platinum-Doublet Chemotherapy in Non-squamous NSCLC Patients with Asymptomatic Untreated Brain Metastases.non-small cell lung cancerJPRN-UMIN000009828Osaka Prefectural Medical Center for Respiratory and Allergic Diseases25
已完成
2 期
Phase II Study of Bevacizumab in Combination with Carboplatin plus oral S1 in Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerChemo-Naive Patients with Non-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000003698Hyogo Cancer Center,Depatrment of Thoracic Oncology45
进行中（未招募）
不适用
Phase II clinical study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic breast cancerMetastatic or locally recurrent HER2-negative breast cancerMedDRA version: 12.0Level: LLTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10006198Term: Breast cancer recurrentEUCTR2009-016062-82-HUSOUTH EASTERN EUROPEAN RESEARCH ONCOLOGY GROUP88
已完成
2 期
A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIson-squamous Non-small-cell Lung CancerJPRN-UMIN000003263Hanshin Cancer Study Group30